<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508259</url>
  </required_header>
  <id_info>
    <org_study_id>15-0134</org_study_id>
    <nct_id>NCT02508259</nct_id>
  </id_info>
  <brief_title>University of California, San Diego (UCSD) Suramin Treatment Trial for Autism</brief_title>
  <official_title>The UCSD Suramin Autism Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the safety and efficacy of a single, intravenous dose of
      suramin in autism spectrum disorders (ASD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to test a new theory of the origin and treatment of ASD. In this
      theory, ASD is caused by both genes and environment interacting to produce a persistent cell
      danger response (CDR; Naviaux RK, 2014) that interferes with and alters normal child brain
      development. Gut microbiome and immune systems are also affected. In this theory, the
      pathological persistence of the cell danger response is traceable to mitochondria, and
      maintained by purinergic signaling mediated by the release of extracellular nucleotides like
      adenosine triphosphate (ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP), and
      uridine diphosphate (UDP). Suramin inhibits excess purinergic signaling by acting as a
      competitive inhibitor of nucleotide signaling at both ionotropic purinergic (P2X) receptors,
      and G-protein coupled, metabotropic purinergic (P2Y) receptors. Suramin has been found to
      correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic
      and environmental mouse models of autism (Naviaux JC, et al. 2015; Naviaux JC, et al. 2014;
      Naviaux RK, et al. 2013). This study will test the safety and efficacy of a single dose of
      suramin in children with ASD. While it is not anticipated that a single dose will produce
      benefits for more than a few weeks, if successful, this study may lead to the development of
      newer and safer drugs for autism treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Joint social attention</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>ADOS (autism diagnostic observation schedule) reciprocal social interaction domain scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Receptive language</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Peabody picture vocabulary test (PPVT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social interaction</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Blinded examiner scoring of video recorded ADOS evaluations using elements of the Communication and Symbolic Behavior Scales (CSBS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expressive language</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Expressive one word picture vocabulary test (EOWPVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical connectivity</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>EEG power and coherence analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic nervous system balance</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>EKG analysis of heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Praxia and Motor coordination</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Fine motor and gross motor digital balance board and dynamic gait analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant behaviors</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Aberrant behavior checklist (ABC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autism core and secondary symptoms</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Autism treatment evaluation checklist (ATEC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clinical Global Impression - improvement scale (CGI-I)</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>7-point scale reflecting the change in core autism behaviors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of child developmental behaviors</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Child behavior checklist (CBCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repetitive Behaviors</measure>
    <time_frame>2 days to 6 weeks</time_frame>
    <description>Repetitive behavior questionnaire (RBQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Suramin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 ml of saline by intravenous infusion over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suramin</intervention_name>
    <description>20 mg/kg IV in 50 ml saline over 30 minutes</description>
    <arm_group_label>Suramin</arm_group_label>
    <other_name>Germanin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>50 ml IV over 30 minutes</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autism diagnostic observation schedule (ADOS) score of ≥ 7

          -  Diagnosis of autism spectrum disorder by Diagnostic and Statistical Manual, 5th
             edition (DSM-V)

          -  Stable treatment and diet regimen for ≥ 2 months

          -  Resident of San Diego region

        Exclusion Criteria:

          -  Any prescription medications

          -  Hospitalization within the previous 2 months

          -  Active medical problem such as seizures, heart, liver, kidney, or adrenal disease

          -  Planning to start a new drug, diet, or behavioral intervention during the study

          -  Weight under the 5th percentile for age

          -  Unable to tolerate venipuncture, urine collection, or an indwelling intravenous
             catheter for 3-4 hours

          -  Plasma creatinine ≥ 1.4 mg/dl

          -  Liver function alanine amino transferase (ALT) or aspartate amino transferase (AST) ≥
             1.5-fold above the upper limit of normal

          -  Known intolerance to suramin or other antipurinergic drugs

          -  Unable to perform or cooperate with study requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert K Naviaux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego School of Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Naviaux JC, Wang L, Li K, Bright AT, Alaynick WA, Williams KR, Powell SB, Naviaux RK. Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. Mol Autism. 2015 Jan 13;6:1. doi: 10.1186/2040-2392-6-1. eCollection 2015.</citation>
    <PMID>25705365</PMID>
  </reference>
  <reference>
    <citation>Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, Naviaux RK. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 2014 Jun 17;4:e400. doi: 10.1038/tp.2014.33.</citation>
    <PMID>24937094</PMID>
  </reference>
  <reference>
    <citation>Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, Schuchbauer MA, Rogac M, Tang Q, Dugan LL, Powell SB. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. PLoS One. 2013;8(3):e57380. doi: 10.1371/journal.pone.0057380. Epub 2013 Mar 13.</citation>
    <PMID>23516405</PMID>
  </reference>
  <reference>
    <citation>Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014 May;16:7-17. doi: 10.1016/j.mito.2013.08.006. Epub 2013 Aug 24. Review.</citation>
    <PMID>23981537</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Robert K. Naviaux</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mitochondria</keyword>
  <keyword>purinergic signaling</keyword>
  <keyword>cell danger response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Safety, metabolomic, and completed outcome data will be made available to qualified institutional groups after peer review and publication.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>May 1, 2017</submitted>
    <returned>June 1, 2017</returned>
    <submitted>June 20, 2017</submitted>
    <returned>July 18, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

